Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology

被引：204

作者：

Bolea-Alamanac, Blanca ^{[1
]}

Nutt, David J. ^{[2
]}

Adamou, Marios ^{[3
]}

Asherson, Phillip ^{[4
]}

Bazire, Stephen ^{[5
]}

Coghill, David ^{[6
]}

Heal, David ^{[7
]}

Mueller, Ulrich ^{[8
]}

Nash, John ^{[9
]}

Santosh, Paramala ^{[10
]}

Sayal, Kapil ^{[11
]}

Sonuga-Barke, Edmund J. S. ^{[12
]}

Young, Susan J. ^{[2
]}

机构：

[1] Univ Bristol, Bristol BS1 3NY, Avon, England

[2] Univ London Imperial Coll Sci Technol & Med, London, England

[3] South West Yorkshire Trust, Wakefield, England

[4] Inst Psychiat, London, England

[5] Norfolk & Suffolk NHS Fdn Trust, Norwich, Norfolk, England

[6] Univ Dundee, Dundee, Scotland

[7] RenaSci Consultancy Ltd, Nottingham, England

[8] Univ Cambridge, Cambridge, England

[9] Mental Healthcare UK, Denbigh, Denbighshire, Wales

[10] Ctr Intervent Paediat Psychopharmacol, London, England

[11] Univ Nottingham, Nottingham NG7 2RD, England

[12] Univ Southampton, Southampton, Hants, England

来源：

JOURNAL OF PSYCHOPHARMACOLOGY | 2014年 / 28卷 / 03期

关键词：

ADD; attention deficit and hyperactivity disorder; ADHD; BAP; hyperkinetic disorder; GENOME-WIDE ASSOCIATION; PERVASIVE DEVELOPMENTAL DISORDERS; GUANFACINE EXTENDED-RELEASE; MAJOR LIFE ACTIVITIES; DEFICIT/HYPERACTIVITY DISORDER; LISDEXAMFETAMINE DIMESYLATE; DOUBLE-BLIND; ADULT ADHD; DOPAMINE TRANSPORTER; CONTROLLED-TRIAL;

D O I：

10.1177/0269881113519509

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.

引用

页码：179 / 203

页数：25

共 175 条

[1] Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder [J].